Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Making Progress for Myelodysplastic Syndromes

    ... made some progress with current medications like Vidaza ( azacitidine ), Dacogen ( decitabine ), Revlimid ( lenalidomide ...

    Article last updated 07/26/2017 - 10:25am.

  2. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

    ... AIM: Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were ... of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS: In this ...

    Research Article last updated 02/03/2017 - 10:05am.

  3. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

    ... activity in patients with MDS and in vitro synergy with azacitidine . METHODS: A phase 2 randomized, placebo -controlled clinical trial of azacitidine and pracinostat was conducted in patients who had International ...

    Research Article last updated 02/03/2017 - 11:12am.

  4. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

    ... or transformation to acute myeloid leukemia (AML). Azacitidine was the first DNA hypomethylating agent approved by the United ... survival is independent of achieving a complete remission. Azacitidine has been used in older patients with both clinical and ...

    Research Article last updated 02/01/2017 - 8:17am.

  5. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.

    Journal Title:  Haematologica Primary Author:  Woo J Author(s):  Woo J, Howar...

    Research Article last updated 03/09/2017 - 1:43pm.

  6. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

    ... The hypomethylating agents (HMAs) azacitidine and decitabine are both approved for treatment of ... on the HMA received in adjusted analysis (decitabine versus azacitidine, hazard ratio = 1·06, 95% confidence interval: 0·94-1·19, ...

    Research Article last updated 10/06/2016 - 11:34am.

  7. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... leukemia (AML). Although the hypomethylating agent azacitidine prolongs survival among patients with higher risk (HR)-MDS ...

    Research Article last updated 02/21/2017 - 9:34am.

  8. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    ... the combination of vadastuximab talirine (SGN-CD33A) and azacitidine in subjects with previously untreated International ... of vadastuximab talirine (SGN-CD33A) in combination with azacitidine (in the open-label Phase 1 portion), and to compare the overall ...

    Clinical Trial last updated 06/19/2017 - 2:44pm.

  9. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... in TET2 molecule show better response to treatment with azacitidine . IDH and DNMT3A mutations are associated with a good response ...

    Research Article last updated 02/01/2017 - 8:15am.

  10. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase ...

    Research Article last updated 12/09/2015 - 8:56am.